摘要:
A procedure which involves the production of extracellular domains (or larger parts including these domains) of human muscle acetylcholine receptor (AChR) expressed in heterologous or homologous systems and obtained in sufficiently folded state appropriate for binding major fractions of anti-AChR antibodies in myasthenia gravis (MG) patients and of immunoadsorbing these antibodies when said polypeptides are used as permanently immobilized on insoluble matrixes. This procedure allows the ex vivo selective elimination of the antibodies against human muscle acetylcholine receptor (AChR), as a replacement and improvement of the non-specific plasmapheresis or Ig apheresis, for the temporary repeated treatment of the disease MG.
摘要:
A method of detecting the presence of a target molecule in a biological sample from a subject, wherein the target molecule is capable of binding to a binding molecule, wherein the method comprises the steps of: a) subjecting the biological sample to a purification step to provide an enriched target molecule sample, wherein the purification step comprises: i) contacting binding molecules with the biological sample to enable binding of the target molecules to the binding molecules, and ii) removing target molecules from the binding molecules to provide the enriched target molecule sample; and b) subjecting the enriched target molecule sample to an assay to detect the presence of the target molecule.
摘要:
A procedure which involves the production of extracellular domains (or larger parts including these domains) of human muscle acetylcholine receptor (AChR) expressed in heterologous or homologous systems and obtained in sufficiently folded state appropriate for binding major fractions of anti-AChR antibodies in myasthenia gravis (MG) patients and of immunoadsorbing these antibodies when said polypeptides are used as permanently immobilized on insoluble matrixes. This procedure allows the ex vivo selective elimination of the antibodies against human muscle acetylcholine receptor (AChR), as a replacement and improvement of the non-specific plasmapheresis or Ig apheresis, for the temporary repeated treatment of the disease MG.